U
Upstream Bio, Inc. (UPB)
NMS – Real Time Price. Currency in USD
8.95
-0.16 (-1.76%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
8.95
-0.16 (-1.76%)
At close: May 12, 2026, 4:00 PM EDT
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
| Name | Position |
|---|---|
| Dr. Adam Houghton M.B.A., Ph.D. | Chief Business Officer |
| Dr. E. Rand Sutherland M.D., M.P.H. | CEO & Director |
| Meggan Buckwell | Director of Corporate Communications & Investor Relations |
| Mr. Aaron Deykin M.D. | Chief Medical Officer and Head of Research & Development |
| Mr. Michael Paul Gray CPA, MBA | CFO & COO |
| Ms. Allison C. Ambrose J.D. | Senior VP, General Counsel & Secretary |
| Ms. Fang Xie Ph.D. | VP & Head of Biometrics |
| Ms. Lisa Fiering | Senior Vice President of People & Culture |
| Ms. Mersedeh Miraliakbari Pharm.D. | Senior Vice President of Regulatory Affairs & Quality |
| Ms. Stacy Price M.S., P.M.P. | Chief Technology Officer |
| Date | Type | Document |
|---|---|---|
| 2026-04-16 | DEFA14A | defa14a_2026_proxy.htm |
| 2026-03-26 | 8-K | d110609d8k.htm |
| 2026-02-11 | 8-K | d103888d8k.htm |
| 2025-11-05 | S-3ASR | d44481ds3asr.htm |
| 2025-09-02 | 8-K | upb-20250902.htm |
| 2025-08-06 | 8-K | upb-20250806.htm |
| 2025-08-06 | 10-Q | upb-20250630.htm |
| 2025-06-12 | 8-K | upb-20250610.htm |
| 2025-05-06 | 8-K | upb-20250506.htm |
| 2025-04-17 | DEFA14A | defa14a_2025_proxy.htm |